WHAT We’re About

MAPS is a membership-based non-profit research and educational organization with over 1800 members and growing. We assist scientists to design, fund, conduct and report on the risks and benefits of the therapeutic, spiritual, and creative uses of psychedelic drugs and marijuana.

Can you imagine a cultural reintegration of the use of psychedelics and the states of mind they engender?

MAPS is directed by Rick Doblin, Ph.D., who founded MAPS in 1986. Rick earned his Ph.D. in Public Policy from the Kennedy School of Government, Harvard University. His dissertation analyzed the regulation of the medical uses of psychedelics and marijuana.

Since 1995 MAPS has disbursed over $1.5 million dollars to worthy research and educational projects.

HOW We’ve Made a Difference

• On November 2, 2001, after fifteen years of persistent struggle, MAPS obtained FDA-approval for the first U.S. study evaluating MDMA-assisted psychotherapy.

• MAPS opened an FDA Drug Master File for MDMA. This is required before any drug can be researched in FDA-approved human studies.

• MAPS assisted Dr. Charles Grob to design, obtain approval for and fund the first FDA-approved study in the U.S. to administer MDMA to humans.

• MAPS assisted in the design and is funding the world’s first government-approved scientific study of the therapeutic use of MDMA (Spain).

• MAPS sponsored the first studies to analyze the purity and potency of street samples of “Ecstasy” and medical marijuana.

• MAPS funded the successful efforts of Dr. Donald Abrams to obtain approval for the first human study in 15 years into the therapeutic use of marijuana, along with a $1 million grant from the National Institute on Drug Abuse.

PROJ ECTS in Need of Support

MDMA-assisted psychotherapy in the treatment of Posttraumatic Stress Disorder (PTSD), Dr. Michael Mitroofer, M.D., Charleston, South Carolina. $225,000 needed

MDMA-assisted psychotherapy in the treatment of Posttraumatic Stress Disorder (PTSD), Pedro Sopelana, M.D., Jose Carlos Bouso, Ph.D. (c), University Autonoma de Madrid, Spain. $40,000 funded by MAPS— $25,000 needed

Marijuana

Analysis of the effectiveness of marijuana vaporizers as compared to combustion in reducing particulate matter and carbon monoxide. $37,000 funded by MAPS— $25,000 needed

The preparation of applications to the National Institutes of Health to investigate the medical uses of marijuana, including migraine, pain, movement disorders, and appetite stimulation. $12,500 funded by MAPS— $15,000 needed

Psilocybin

Pilot study of psilocybin for the treatment of Obsessive-Compulsive Disorder. Francisco Moreno, M.D., University of Arizona, Tucson. $12,500 funded by MAPS— $12,500 needed

Ketamine

Ketamine for the treatment of heroin addiction, single v. multiple treatment sessions. Evgeny Krupitsky, M.D., Leningrad Regional Center for Alcoholism and Drug Addiction Therapy, Russia. $22,500 funded by MAPS— $30,000 needed

LSD

Protocol development for LSD-assisted psychotherapy in patients facing terminal illness. Richard Yensen, Ph.D., and Donna Dryer, M.D. Baltimore, Maryland $10,000 funded by MAPS— $10,000 needed

Policy makers stay current with MAPS — shouldn’t you?

“I believe that if people would learn to use LSD’s vision-inducing capability more wisely, under suitable conditions, in medical practice and in conjunction with meditation, then in the future this problem child could become a wonder child.”

– Dr. Albert Hofmann

BENEFITS of Membership

As a (confidential) member of MAPS, you’ll receive the quarterly MAPS Bulletin. In addition to reporting on the latest research in both the U.S. and abroad, the Bulletin includes feature articles, personal accounts, book reviews, and reports on conferences and allied organizations. MAPS members are invited to participate in a vital on-line mailing list and to visit our website, which includes protocols, bibliographies, books, news and more.

Basic Plus, Supporting, and Patron Members can choose a free copy of: LSD Psychotherapy: by Stanislav Grof, M.D. Second paperback edition with a Foreword by Andrew Weil, M.D., 40 color plates (8 new), 352 pages. A valuable source of information for those involved with LSD in any way – parents, teachers, researchers, legislators, or students of the human psyche.

Student/Low Income— $20  
Basic Membership— $35  
Basic Plus Membership— $50  
Supporting Membership— $100  
Patron Membership— $250+

Unless otherwise indicated your donation will be considered an unrestricted gift to be used to fund high-priority projects. If you wish, however, you may direct contributions to a specific study. Your tax-deductible donation may be made by credit card or check made out to MAPS. Gifts of stock are welcome, as are trust and estate planning options.

The MAPS mailing list is strictly confidential and is not available for purchase. The MAPS Bulletin is mailed in a plain envelope.

Front cover art by Alex Grey. Posters and books are available: 725 Union St. Brooklyn, NY 11215; http://www.alexgrey.com

MAPS has positioned itself at the center of the conflict between scientific exploration and the politically-driven strategy of the War on Drugs.

MAPS is the only membership organization supporting this crucial research.

Join us—your financial support is needed to translate hard-won scientific freedom into new research results and possibilities.

If we don’t support the cultural reintegration of psychedelics and marijuana through good science, who will?

Multidisciplinary Association for Psychedelic Studies  
2105 Robinson Avenue  
Sarasota, FL 34232  
Tel: 941-924-MAPS (6277) or 888-868-6277  
E-mail: info@maps.org  
Please visit our website: www.maps.org

“Mystery is at the heart of existence and it is something that one experiences very profoundly as part of the psychedelic vision. MAPS seeks to explore that mystery through scientific research.”

— Andrew Weil, M.D.